IMVT
Immunovant, Inc.
$34.15
+0.02
(+0.06%)
Mkt Cap
7.01B
Volume
1,650,773
52W Range
13.79-36.285
Sector
Healthcare
Beta
0.70
EPS (TTM)
-2.78
P/E Ratio
-8.96
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (505.61M) | (413.84M) | (259.34M) | (210.96M) | (156.73M) | (107.43M) | (66.39M) | (448) | (136.74M) |
| EPS | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.68 |
| Free Cash Flow | (407.32M) | (376.63M) | (214.59M) | (188.39M) | (106.37M) | (83.54M) | (53.39M) | (28.60M) | (128.30M) |
| FCF / Share | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 | -0.95 | -1.24 | -1.99 | -12.83 |
| Operating CF | (407.31M) | (375.87M) | (214.23M) | (188.19M) | (106.11M) | (83.33M) | (53.36M) | (28.55M) | (128.30M) |
| Total Assets | 957.57M | 776.22M | 666.71M | 405.84M | 515.56M | 412.49M | 109.39M | 405,000 | 113,170 |
| Total Debt | 72,000 | 98,000 | 138,000 | 1.22M | 2.36M | 3.42M | 3.19M | 300,000 | 0 |
| Cash & Equiv | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M | 325,000 | 0 |
| Book Value | 852.59M | 707.45M | 617.76M | 362.49M | 469.82M | 391.48M | 94.07M | 24,552 | (1.50M) |
| Return on Equity | -0.59 | -0.58 | -0.42 | -0.58 | -0.33 | -0.27 | -0.71 | -0.02 | N/A |
| Metric | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (147.86M) | (110.64M) | (126.50M) | (120.61M) | (106.45M) | (111.12M) | (109.12M) | (87.15M) | (75.32M) | (51.42M) | (58.66M) | (73.94M) |
| EPS | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 | -0.76 | -0.74 | -0.60 | -0.52 | -0.36 | -0.45 | -0.57 |
| Free Cash Flow | (95.07M) | (92.33M) | (102.52M) | (117.41M) | (110.84M) | (100.57M) | (88.84M) | (76.38M) | (59.85M) | (47.23M) | (60.09M) | (47.41M) |
| FCF / Share | -0.47 | -0.51 | -0.59 | -0.69 | -0.73 | -0.68 | -0.61 | -0.52 | -0.41 | -0.33 | -0.46 | -0.36 |
| Operating CF | (95.06M) | (92.33M) | (102.52M) | (117.41M) | (110.64M) | (100.39M) | (88.65M) | (76.20M) | (59.70M) | (47.10M) | (60.06M) | (47.37M) |
| Total Assets | 957.01M | 1.05B | 582.96M | 661.44M | 776.22M | 420.93M | 515.71M | 589.68M | 666.71M | 711.45M | 292.07M | 351.22M |
| Total Debt | 72,000 | 0 | 0 | 0 | 98,000 | 23,000 | 47,000 | 69,000 | 138,000 | 306,000 | 614,000 | 919,000 |
| Cash & Equiv | 902.11M | 994.52M | 521.87M | 598.91M | 713.97M | 374.69M | 472.94M | 560.00M | 635.37M | 690.94M | 269.93M | 329.96M |
| Book Value | 852.59M | 986.13M | 519.71M | 608.54M | 707.45M | 352.62M | 449.05M | 544.66M | 617.76M | 679.34M | 251.81M | 299.87M |
| Return on Equity | -0.17 | -0.11 | -0.24 | -0.20 | -0.15 | -0.32 | -0.24 | -0.16 | -0.12 | -0.08 | -0.23 | -0.25 |
IMVT News
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Q4 Earnings Call Highlights
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints